Emerald Bioscience (OTCMKTS:EMBI) Shares Down 6.6% – Here’s What Happened

Emerald Bioscience Inc. (OTCMKTS:EMBI) shares traded down 6.6% during trading on Tuesday . The company traded as low as $0.8026 and last traded at $0.8136. 197,253 shares traded hands during trading, a decline of 99% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.8712.

Emerald Bioscience Price Performance

The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.43. The firm has a market cap of $218.11 million, a PE ratio of -10.17 and a beta of 0.43. The business’s 50 day moving average is $0.76.

About Emerald Bioscience

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.